CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
[18F] FLTdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01244737
NCT01244737Phase 2Completed
CompareCT.gov

Phase 2 Study of [18F]FLT for PET Imaging of Brain Tumors in Children

Frederick Daniel Grant·interventional·Posted Nov 19, 2010·Updated Jul 11, 2024

In Brief

A Phase 2 clinical trial evaluating [18F] FLT for Brain Neoplasms. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is important in the management of these tumors, but current imaging methods have limitations in providing the necessary information for optimal treatment of these patients. The goal of this study is to evaluate the potential utility of positron emission tomography (PET) with 3'-deoxy-3'-\[F-18\] fluorothymidine (18F-FLT) in the medical management of brain tumors in children. Funding source - FDA Office of Orphan Product Development (OOPD)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Neoplasms
CountriesUnited States
CollaboratorsDana-Farber Cancer Institute

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 19, 2010
Enrollment StartOct 1, 2010
Primary CompletionFeb 5, 2023
TodayJul 2, 2026
Enrollment to primary: 12.3 yearsPosted 15.6 years ago

Interventions

[18F] FLTdrug

\[18F\] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan